Fig. 2: PDAC cancer cells express ligands for the myeloid receptors Siglec-7 and Siglec-9. | Nature Communications

Fig. 2: PDAC cancer cells express ligands for the myeloid receptors Siglec-7 and Siglec-9.

From: Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9

Fig. 2

A–B Expression of Siglec-7 and Siglec-9 ligands in PDAC cancer cell lines evaluated by flow cytometry (A) and ELISA (B). In ELISA, the positive control for each Siglec-hFc was set as 100%. Representative results of three independent experiments. C, D Characterisation of Siglec ligands by using (C) glycosylation inhibitors and (D) knock down of different a2,3 sialyltransferases. Mean of control siRNA was set as 100%. Statistics: Pairwise comparisons of each condition against the respective control using Two-way ANOVA with Dunnett’s multiple comparisons test (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001). E Survival analysis of PDAC patients based on the mean expression of ST3GAL1 and ST3GAL4 using the Log-rank test in the TCGA-PAAD data set. Top and bottom thirds of the mean expression were used to define high and low expression, respectively. F Expression of Siglec receptors in different cell populations present in PDAC tumours in scRNA-Seq from Peng et al. G Immunofluorescent staining of Siglec-7 and Siglec-9 receptors in PDAC. Representative staining of n = 6 PDAC patients.

Back to article page